Skip to content
  • Argentina
  • Brazil
  • Canada
  • Chile
  • Colombia
  • Europe
  • France
  • Germany
  • India
  • Italy
  • Japan
  • Korea
  • Mexico
  • Perú
  • Russia
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
  • Vietnam
  • Italia
    • Utenti registrati
    • 0039 0424-472449 Richiedi informazioni
    • 0039 0424-472449 Richiedi informazioni
    ItalyItaly
      • Part of brands: |
        • Guida
          • Prevenzione di malattie ereditarie
          • Gravidanza serena
        • I nostri servizi
          • Per gli specialisti della salute
          • Per i pazienti
        • Diagnostica
        • Chi Siamo
          • Igenomix Research
          • Chi siamo
        • Webinars
        Genomics Precision Diagnostic > Neurology Precision Panel > Neurofibromatosis Precision Panel

        Neurofibromatosis  Precision Panel

        Neurofibromatosis type 1 (NF1) and type 2 (NF2) are neurocutaneous congenital disorders that affect organs of ectodermal origin including skin, central nervous system, and the eyes.
        Overview
        Indication
        Clinical Utility
        Genes & Diseases
        Methodology
        References

        Overview

        • Neurofibromatosis type 1 (NF1) and type 2 (NF2) are neurocutaneous congenital disorders that affect organs of ectodermal origin including skin, central nervous system, and the eyes. All are inherited in an autosomal dominant pattern and are characterized by a high rate of mutational change occurring for the first time in an individual as well as variable expression. NF1 and NF2 differ with regards to their age of onset, clinical manifestations, gene loci, and gene protein products. However, in both conditions, the altered gene products have a crucial role in the dysregulation of tumor suppression. NF1, also known as von Recklinghausen syndrome, includes effects on multiple systems of the body and the major associated tumor is the neurofibroma. In addition, clinical manifestations include bone dysplasia, learning disabilities, and increased risk of malignancy. NF2 includes schwannomas of multiple cranial and spinal nerves, among others.   
        • The Igenomix Neurofibromatosis Precision Panel  can serve as a diagnostic tool ultimately leading to a better management and prognosis of the disease. It provides a comprehensive analysis of the genes involved in this disease using next-generation sequencing (NGS) to fully understand the spectrum of relevant genes involved, and their high or intermediate penetrance. 

        Indication

        • The Igenomix Neurofibromatosis Precision Panel is indicated in patients with a clinical suspicion or diagnosis of Neurofibromatosis type 1 or type 2 presenting with the following manifestations: 
          • Multiple neurofibromas 
          • Café au lait spots 
          • Lisch nodules (pigmented iris hamartomas) 
          • Seizures and/or focal neurologic signs 
          • Intellectual disability 
          • Bone involvement: scoliosis, short stature, fractures, cortical thinning etc 
          • Associated with other tumors: pheochromocytoma, Wilms tumor, meningiomas, ependymomas 
          • Bilateral vestibular schwannomas (acoustic neuroma)
          • Early-onset cataracts 

        Clinical Utility

        The clinical utility of this panel is: 

        • The genetic and molecular diagnosis for an accurate clinical diagnosis of a symptomatic patient.  
        • Early initiation of treatment with a multidisciplinary team for appropriate surveillance for malignancy, appropriate laser treatment and/or chemotherapy, surgical resection of tumors as well as orthopaedic intervention. 
        • Risk assessment of asymptomatic family members according to the mode of inheritance .
        • Improved pathways from diagnosis to treatment in susceptible populations. 

        Genes & Diseases

        Methodology

        References

        See scientific referrals

        Plotkin, S. R., & Wick, A. (2018). Neurofibromatosis and Schwannomatosis. Seminars in neurology, 38(1), 73–85. https://doi.org/10.1055/s-0038-1627471 

        Korf B. R. (2013). Neurofibromatosis. Handbook of clinical neurology, 111, 333–340. https://doi.org/10.1016/B978-0-444-52891-9.00039-7 

        Spyk, S., Thomas, N., Cooper, D., & Upadhyaya, M. (2011). Neurofibromatosis type 1-associated tumours: Their somatic mutational spectrum and pathogenesis. Human Genomics, 5(6), 623. doi: 10.1186/1479-7364-5-6-623 

        Pemov, A., Dewan, R., Hansen, N., Chandrasekharappa, S., Ray-Chaudhury, A., & Jones, K. et al. (2020). Comparative clinical and genomic analysis of neurofibromatosis type 2-associated cranial and spinal meningiomas. Scientific Reports, 10(1). doi: 10.1038/s41598-020-69074-z 

        Farschtschi, S., Mautner, V. F., McLean, A., Schulz, A., Friedrich, R. E., & Rosahl, S. K. (2020). The Neurofibromatoses. Deutsches Arzteblatt international, 117(20), 354–360. https://doi.org/10.3238/arztebl.2020.0354 

        Cimino, P. J., & Gutmann, D. H. (2018). Neurofibromatosis type 1. Handbook of clinical neurology, 148, 799–811. https://doi.org/10.1016/B978-0-444-64076-5.00051-X 

        descargar

        Detail description

        Download

        BROCHURE

        Download

        Request Information


        • reCAPTCHA demo: Simple page

        GUIDA

        Fertilità
        Prevenzione di malattie ereditarie
        Gravidanza serena

        I NOSTRI SERVIZI

        Soluzioni genetiche
        Informazioni sulla genetica

        PANORAMICA

        Informazioni su Igenomix
        Contatti
        Come inviare un campione
        Qualità
        Lavora con noi
        News and Press

           0039 0424-472449
        Contatti
        • Argentina
        • Brazil
        • Canada
        • Chile
        • Colombia
        • Europe
        • France
        • Germany
        • India
        • Italy
        • Japan
        • Korea
        • Mexico
        • Perú
        • Russia
        • Spain
        • Taiwan
        • The Middle East
        • Turkey
        • United Kingdom
        • United States
        • Vietnam
        Linguaggio

        [2019] © Igenomix Politica sulla privacyPolitica qualità Politica dei cookie       Soddisfazione       Manuale dell’utente

        Richiedi informazioni








        • reCAPTCHA demo: Simple page











        • Guida
          • Prevenzione di malattie ereditarie
          • Gravidanza serena
        • I nostri servizi
          • Per gli specialisti della salute
          • Per i pazienti
        • Diagnostica
        • Chi Siamo
          • Igenomix Research
          • Chi siamo
        • Webinars
        • Italia
        • Utenti registrati
        • Area pazienti
        • Area cliniche

        We are using cookies to give you the best experience on our website.

        You can find out more about which cookies we are using or switch them off in settings.

        Italy
        Powered by  GDPR Cookie Compliance
        Privacy Overview

        This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

        Strictly Necessary Cookies

        Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

        If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.